Superluminal Medicines Inc. has commenced IND-enabling studies for its lead program, an orally administered, highly selective, biased melanocortin MC4 receptor (MC4R) agonist initially targeting rare genetic forms of obesity and hypothalamic obesity, with potential as a treatment for general obesity in combination with GLP-1 drugs. IND submission is expected in the second half of 2026.